Cathie Wood’s ARK ETF adjusts portfolio with key stock trades By Investing.com

Cathie Wood’s ARK ETFs have disclosed their daily trades for Tuesday, June 11th, 2024, revealing a series of strategic moves that saw the funds buying and selling across various sectors. Leading the activity was the sale of EXACT SCIENCES CORP (NASDAQ:EXAS) shares, as the ETFs offloaded a total of 55,858 shares, resulting in a substantial outflow of $2,395,749. This move comes amidst a pattern of selling the stock, as ARK also reduced its position in EXACT SCIENCES CORP on the previous trading days.

In contrast to the divestment in EXACT SCIENCES CORP, ARK showed a bullish stance on INTELLIA THERAPEUTICS INC (NASDAQ:NTLA), acquiring 57,128 shares valued at $1,329,939. This purchase continues a trend of accumulation, as ARK has been consistently increasing its stake in the company over the last week.

Another notable trade involved ARK’s investment in VERVE THERAPEUTICS INC (NASDAQ:VERV), where the funds sold 220,656 shares, totaling $1,182,716. This sell-off also aligns with ARK’s recent trading pattern, indicating a strategic exit from the position.

On the buying side, ARK added 91,412 shares of PACIFIC BIOSCIENCES OF CALIFORNIA INC (NASDAQ:PACB) to its portfolios, with the transactions amounting to $172,768. Additionally, the ETFs continued to build their holdings in ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ:ARCT), purchasing 30,375 shares for a total of $968,658, which follows a significant investment in the company on the previous day.

Other investments included the purchase of 25,969 shares of BEAM THERAPEUTICS INC (NASDAQ:BEAM) for $633,643, and 28,398 shares of PAGERDUTY INC (NYSE:PD) for $569,947. These trades indicate ARK’s continued confidence in the genomic and technology sectors.

Smaller transactions included the acquisition of 6,200 shares of MARKFORGED HOLDING CORP (NYSE:MKFG) at a modest value of $2,758 and 1,275 shares of VERACYTE INC (NASDAQ:VCYT) for $26,621.

Investors following Cathie Wood’s ARK ETFs will notice the strategic rebalancing taking place, with a clear focus on certain biotechnology stocks and a retreat from others.

The consistent investment in companies like INTELLIA THERAPEUTICS INC suggests a strong belief in their long-term potential, while the divestment from stocks like EXACT SCIENCES CORP and VERVE THERAPEUTICS INC may reflect a change in ARK’s assessment of their future prospects. As always, ARK’s trades provide a window into the fund’s evolving investment strategy, which is closely watched by market participants for insights into emerging trends and sector opportunities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.